JerMa88/BMC_Womens_Health_Peer_Reviews huggingface dataset:
Title: The relationship between vaccine hesitancy and health literacy in pregnant women: a
cross-sectional study
Version: 0 Date: 15 Dec 2023
Reviewer:  Sandeep Poddar
Reviewer's report:
1.
There is no references of 2023
Advised to add the following and similar references
Sham, F., Shahed, A. N. M., Baharudin, N. S., Majid, N., & Yajid, S. (2023). Covid-19
Vaccination Acceptance and Its Associated Factors among Community in Kelantan. The
Malaysian Journal of Nursing (MJN), 15(Supplimentary 1), 125-138.
Theresia, S. I. M., & Reñosa, M. D. C. (2023). Accelerating COVID-19 Vaccination Amid
Natural Disasters in Indonesia. The Malaysian Journal of Nursing (MJN), 14(3), 201-208.
Mitchell, S. L., Schulkin, J., & Power, M. L. (2023). Vaccine hesitancy in pregnant Women:
A narrative review. Vaccine.
Moschese, V., De Angelis, L., Capogna, M. V., Graziani, S., Baglivo, F., Pietropolli, A., ... &
Rizzo, C. (2023). Vaccine hesitancy and knowledge regarding maternal immunization among
reproductive age women in central Italy: a cross sectional study. Frontiers in Global Women's
Health, 4.
2.
The time period or data collection year is not mentioned- advised to mention.
3.
The vaccine names included in the study need to clearly state in materials methods--(example :
flu vaccine etc.)
4.
There are several works done on the same topic-- so highlight the main outcome of this article
specifically.
Title: The relationship between vaccine hesitancy and health literacy in pregnant women: a
cross-sectional study
Version: 4 Date: 02 Apr 2024
Reviewer's report:
The article has been improved following corrections made after the review, although I
recommend some additional modifications.
1. It would be useful to describe whether there were any limitations on the number of weeks of
gestation of participants, or whether a range was established for their participation in the study.
2. It would be useful to explain why the selection of pregnant women was made from those
women who attended the hospital, bearing in mind that subsequent access to the surveys to be
completed was through maternity education.
3. It is advisable to clarify whether participation was offered exclusively to the 230 pregnant
women or whether there were pregnant women who refused to participate in the study before
or during data collection.
4. It would be advisable to explain the measures taken to eliminate potential response bias.
5. It is recommended to detail how the quantitative and qualitative variables have been described.
6. It would be advisable to present a flow chart describing the losses.
7. Results obtained in relation to parity and number of births should be discussed.
Title: The relationship between vaccine hesitancy and health literacy in pregnant women: a
cross-sectional study
Version: 4 Date: 04 Apr 2024
Reviewer:  Sandeep Poddar
Reviewer's report:
Dear I have given several references to make the article up to date now I am giving again
including 2024 references, kindly add and make your article more up to date
Please add the followings an discussion section as well
Mitchell, S. L., Schulkin, J., & Power, M. L. (2023). Vaccine hesitancy in pregnant Women: A
narrative review. Vaccine, 41(29), 4220–4227. https://doi.org/10.1016/j.vaccine.2023.05.047
Theresia, S. I. M. ., & C. Reñosa, M. D. . (2023). Accelerating COVID-19 Vaccination Amid
Natural Disasters in Indonesia. The Malaysian Journal of Nursing (MJN), 14(3), 201-208.
https://doi.org/10.31674/mjn.2023.v14i03.024
Moschese V, De Angelis L, Capogna MV, Graziani S, Baglivo F, Pietropolli A, Miraglia Del
Giudice M, Rizzo C and the Italian Society of Pediatric Allergology and Immunology (SIAIP)
Vaccine Committee (2023) Vaccine hesitancy and knowledge regarding maternal immunization
among reproductive age women in central Italy: a cross sectional study. Front. Glob. Womens
Health 4:1237064. doi: 10.3389/fgwh.2023.1237064
Moriarty, K. L., Oyenuga, R. O., Olafuyi, O., & Schwartz, D. A. (2024). Causes and Effects
of COVID-19 Vaccine Hesitancy Among Pregnant Women and its Association with Adverse
Maternal, Placental, and Perinatal Outcomes. The Yale journal of biology and medicine, 97(1),
73–84. https://doi.org/10.59249/LPOQ5146
Uluda#, E., Serçeku#, P., Y#ld#r#m Gök#en, D. F., Alata#, S. E., & Özkan, S. (2024).
Is decision-making based on the internet during pregnancy a predictive factor for vaccine
hesitancy in pregnant women during the pandemic? Women & Health, 64(1), 5–13. https://
doi.org/10.1080/03630242.2023.2277879
Title: Genetically predicted high sex hormone binding globulin was associated with decreased
risk of polycystic ovary syndrome
Version: 0 Date: 09 Oct 2023
Reviewer:  Olivier Valkenburg
Reviewer's report:
This study represents a large scale analysis of the probable and causal relationship between
SHBG level and PCOS risk. The study has been performed in-silico in a large set of study
subjects. Results were validated in a second cohort. The report is well-written and consice.
It's results are meaningful and relevant to the (clinical ) study of PCOS and/or anovulatory
subfertility. The statistical techniques that were applied are very complicated. At first glance,
they seem to be relevant and applied in correct fashion. Although this reviewer is cautious on
this matter and would appreciate a back-up.
Title: Genetically predicted high sex hormone binding globulin was associated with decreased
risk of polycystic ovary syndrome
Version: 0 Date: 30 Oct 2023
Reviewer's report:
It is an interesting study. I wonder whether the authors considered diagnosing canalization of
the study.
What is the 95% uncertainty interval in the section of introduction?
In addition, the authors should proofread writing to catch formatting errors.
Title: Genetically predicted high sex hormone binding globulin was associated with decreased
risk of polycystic ovary syndrome
Version: 1 Date: 05 Dec 2023
Reviewer's report:
In two-sample Mendelian randomization (MR) analyses, considering canalization is important.
The authors should discuss it in the manuscript.
Defining 95%  uncertainty intervals (UIs) using the 25th and 975th ordered 1000 draw values
of the posterior distribution is a specific approach commonly used in Bayesian statistics. The
authors should clearly define it according to the cited reference, to avoid misinterpretation.
Title: Genetically predicted high sex hormone binding globulin was associated with decreased
risk of polycystic ovary syndrome
Version: 2 Date: 02 Feb 2024
Reviewer's report:
Comments:
1. Given the volume of existing literature on this topic (Zhu and Goodarzi, 2022), what new
insights or contributions does this manuscript offer?
2. It seems that there is a discrepancy between what the manuscript states about a paper and
what the paper's abstract says. It is mentioned in the manuscript that "For instance, in a study
involving 61 PCOS patients and 91 matched controls, peripheral SHBG levels were significantly
higher in the control group than in the PCOS group [9]".  However, it is mentioned in the abstract
that "Fifty five patients with PCOS diagnosis composed of 25 obese, 13 overweight, 17 normal
weight subjects, and 49 healthy women matched for age and BMI were included in this study
(Dikmen, Tarkun, Ozturk, Arslan, Canturk, 2011) ".  A clarification is needed.
3. The authors are advised to thoroughly re-evaluate and verify the accuracy of the literature
review presented in the manuscript.
References
1. Dikmen E, Tarkun I, Ozturk F, Arslan B, Canturk Z. Plasma adiponectin and resistin levels
in women with polycystic ovary syndrome: relation to body mass index and insulin resistance.
Turkish Journal of Medical Sciences. 2011; 41(1):45-52.10.3906/sag-1001-573.
2. Zhu, T., & Goodarzi, M. O. (2022). Causes and Consequences of Polycystic Ovary
Syndrome: Insights From Mendelian Randomization. The Journal of clinical endocrinology and
metabolism, 107(3), e899–e911. https://doi.org/10.1210/clinem/dgab757
Title: Magnitude of psychological distress and associated factors among war survivor women
in Northern, Ethiopia, 2022: A community-based cross- sectional survey
Version: 5 Date: 14 Mar 2024
Reviewer's report:
PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses one or several
testable research questions? (Brief or other article types: is there a clear objective?)
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with sufficient technical rigor to
allow confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
No - there are minor issues
OVERALL MANUSCRIPT POTENTIAL - Has the author addressed your concerns sufficiently
for you to now recommend the work as a technically sound contribution? If not, can further
revisions be made to make the work technically sound?
Probably - with minor revisions
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: Thank you for the opportunity to review this revised paper. I have
carefully reviewed the author's comments and am satisfied with the revisions made. However,
the conclusion could also benefit from expanding future studies and considering the next steps.
The authors state government screening is an important step, but how does this relate to future
research endeavours ?
REQUESTED REVISIONS:
Please revise the conclusion based on my suggestion.
Title: Factors influencing U.S. women’s interest and preferences for breast cancer risk
communication: A cross-sectional study from a large tertiary care breast imaging center
Version: 3 Date: 28 May 2024
Reviewer's report:
The authors present findings from a cross-sectional questionnaire-based study among women
presenting to a single academic center for breast cancer screening, eliciting preferences re:
sharing of breast cancer risk, including methods of communication. The majority of women
preferred to have breast cancer risk communicated to them, though only a minority had received
this information in the past. Some differences emerged by age in particularly regarding methods
of communication and details of communicated risk. Overall this is an interesting study, and
supports further studies in more diverse, larger populations eliciting patient preferences re: breast
cancer risk communication. Some suggested edits/comments:
1. Consider in Figure 2 and in Results text indicating the proportion of women who responded
with multiple options to the question for preferred mechanism for risk communication.
2. I would be careful not to overstate the differences in interest in knowing breast cancer risk by
race/ethnicity – it was only the smallest category, “more than one race or other race,” that had a
significant difference in preference in multivariable analysis. I’m not sure you can try to explain
further than the small #s in this analysis. Without a citation or more diverse cohort to support this,
I would remove the sentence “It is possible that women identifying as “more than one race or
other race” may perceive their breast cancer risk as lower because they have disproportionately
less information and awareness resulting from a lack of representativeness in research.”
3. An additional limitation of this study, beyond that it is single center and in a relatively
homogeneous population, is that it is at an academic center. In the limitations, would also briefly
mention that this can limit generalizability (can list among the other reasons/limitations).
4. In your discussion of methods of communicating risk, I’d also look into the work of Katherine
Crew and Rita Kukafka, who have evaluated web-based decision support tools for patients and
providers to convey breast cancer risk, including among diverse patients. For example, Kukafka
R et al. Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid
in Multi-Ethnic, Low-Numerate Women. JMIR 2015 https://www.jmir.org/2015/7/e165/
5. An optional consideration - You might also want to conduct a literature search for studies that
might have looked at patient preferences regarding risk assessment/communication for other
medical conditions, like ASCVD risk, for example. This might provide context for your findings,
particularly regarding preferred methods of sharing risk and patient-preferred level of detail
about risk, and spark ideas for future directions on how to communicate breast cancer risk.
Title: Factors influencing U.S. women’s interest and preferences for breast cancer risk
communication: A cross-sectional study from a large tertiary care breast imaging center
Version: 4 Date: 07 Jun 2024
Reviewer:  Naomi Noguchi
Reviewer's report:
Thank you for the revision. The paper is more informative now and I am satisfied with all the
changes made in response to the reviewers' comments.
Title: Exploring drivers of women’s well-being in hospitals: mapping the landscape
Version: 5 Date: 26 Feb 2024
Reviewer's report:
PEER REVIEWER ASSESSMENTS:
OBJECTIVE - Full research articles: is there a clear objective that addresses one or several
testable research questions? (Brief or other article types: is there a clear objective?)
Yes - there is a clear objective
DESIGN - Is the current approach (including controls and analysis protocols) appropriate for
the objective?
Yes - the approach is appropriate
EXECUTION - Are the experiments and analyses performed with sufficient technical rigor to
allow confidence in the results?
Yes - experiments and analyses were performed appropriately
STATISTICS - Is the use of statistics in the manuscript appropriate?
Yes - appropriate statistical analyses have been used in the study
INTERPRETATION - Is the current interpretation/discussion of the results reasonable and not
overstated?
No - there are minor issues
OVERALL MANUSCRIPT POTENTIAL - Has the author addressed your concerns sufficiently
for you to now recommend the work as a technically sound contribution? If not, can further
revisions be made to make the work technically sound?
Probably - with minor revisions
PEER REVIEWER COMMENTS:
GENERAL COMMENTS: Thank you for resubmitting the revised paper. You have addressed
most of my comments. However, I'd also like the authors to expand on the conclusion to include
the next steps, future research considerations, and where they would like to see the results of
this study go forward in improving women's well-being in hospitals.
REQUESTED REVISIONS:
Please see my comment about expanding the conclusion of the study.
Title: Psychological Distress and Uterine Fibroids: A Bidirectional Two-Sample Mendelian
Randomization Study
Version: 1 Date: 23 May 2024
Reviewer's report:
I read with great interest the manuscript, which falls within the aim of this Journal and offers
a high-quality overview of the topic.
The abstract satisfactorily summarizes the contents of the manuscript. The methodology is
accurate and the data analysis supports the conclusions. The tables and figures are clear and
interesting.
Although the manuscript can be considered already of high quality, I would suggest taking into
account the following minor recommendations:
- An extensive correction of the English language is necessary. Typos errors should be corrected
(i.e. lines 65, 247, 264...)
- I find it interesting to include a reference to the surgical approach to myomectomy (see PMID:
38581885).
-What do the results of this study add?
-What are the implications of these findings for clinical practice and/or further research? It is
important to report the results obtained by the authors in the context of clinical practice and to
adequately highlight what contribution this study adds to the literature already existing on the
topic and to future study perspectives.
- Discussions can be expanded and improved by citing relevant articles (I suggest authors to
read and insert in references the following article PMID:  37568356).
Title: Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized,
placebo-controlled Phase 2b SCHUMANN study
Version: 1 Date: 08 Feb 2024
Reviewer's report:
Dear Authors,
I read carefully your paper investigating the use of eliaxpixant in the treatment of endometriosis
associated pain.
Overall, I find it interesting any type of investigation thriving for the discovery of a new
treatment of this complex disease.
Regarding your article, despite the novelty of your data, it seemed more of a data reporting rather
than a scientific article. I suggest to make the paper more fluid, focusing on the main findings
and leaving the inessential elements into tables.
The abstract goes straight to the point and is appropriate.
The introduction section is well written, clear and easy to read.
Materials and methods section : please clearly state if the patients were treated with other drugs
other than eliaxpixant and elagolix in the text. Despite the supplementary material, I suggest
describing the international design of the study by providing more details.
The results section should be condensed (length 11 pages), despite the high amount of data
collected. I.e., Figure 1 is highly appreciated.  Table 1 is missing (Line 258). I believe adverse
event are of outmost importance, but you should give less information about them and focus on
the most important ones.
The discussion section is adequate, providing in-depth debate on the main findings.
Title: Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized,
placebo-controlled Phase 2b SCHUMANN study
Version: 1 Date: 08 Feb 2024
Reviewer's report:
Dear authors,
I appreciated the effort in the investigation of a potential new treatment for endometriosis pain,
such as eliapixant.
The investigation is well reported, with clear details of the methods provided in through both
the text and the tables.
The results section should be shortened because it make it difficult to come to the end of the
article.
Regarding the discussion section, I would highlight the need for further research in the field of
new treatment options for endometriosis and the importance of an early diagnosis,  especially in
adolescent/young patients, due to the difficulties in discovering new solid therapeutic medical
options.
Title: Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized,
placebo-controlled Phase 2b SCHUMANN study
Version: 2 Date: 14 May 2024
Reviewer's report:
Dear Authors,
Thank you for the opportunity to review this interesting work aimed at researching new
therapeutic options for endometriosis' patients. The article on the SCHUMANN study, which
aimed to evaluate the efficacy and safety of eliapixant as a potential treatment for endometriosis,
terminated prematurely due to concerns about liver safety, is clear and well-structured. However,
there are some considerations to be made: regarding the symptoms investigated, as it is a study
on endometriosis, it would have been interesting to also evaluate dysuria and dyschezia (to
be included if the data have been analyzed, otherwise, indicate their absence). With regard to
lines 167-168, it would be helpful to indicate if a standardized wash-out period from previous
hormonal therapies was conducted. Regarding the clinical characteristics, it would be useful to
report at least the disease severity grade of the examined patients according to the rASRM Score
for endometriosis.
Title: A longitudinal study of sexual activity and influencing factors in breast cancer patients
during treatment in the southwest of China: a trajectory analysis model
Version: 2 Date: 14 Nov 2023
Reviewer:  Manoj Kalita
Reviewer's report:
1. What is exact meaning of the line “a third class tumor hospital in China”
2. Sample size formula should be used for longitudinal study.
3. Exact P value should be used (p value can’t be 0.000, since it is a probability value), See the
software manual if it is showing 0.000 what to write.
4. Kindly check the line “The variables with P<0.1 in the univariate analysis and the variables
that might be significant” for significance level of p value.
5. Instead of Unsing Logistic regression author is advice to do regresion model   after following
assumtions of parametric/non parametric (Table 4).
Title: A longitudinal study of sexual activity and influencing factors in breast cancer patients
during treatment in the southwest of China: a trajectory analysis model
Version: 3 Date: 29 Apr 2024
Reviewer's report:
A longitudinal study of sexual activity and influencing factors in breast cancer patients during
treatment: a trajectory analysis model
1. The study area should be stated in the title.
2. Abstract:
1.1 Results: The statement said, “The results showed that the older the patients, the higher the
libido and vaginal lubrication scores, the higher the level of sexual activity, and the differences
were statistically significant.” Is redundant, which is in line with the statistical results presented
before it. So, delete it.
2. Introduction
2.1 Still most of the statements in the introductions lacks source. So, you should cite your sources
in the third paragraph.
2.2 It said, "The results Nancy E. Avis‘ study..." under the four paragraph should be rewritten
(Rephrased).
3. Methods
3.1 Description of the study area: The author's provided the data collection method and time.
However, I wasn't asking about the data collection methods in this section but rather about
the descriptions of the study area. The data collection technique should be provided in another
section of the methodology. Which nation or region did this study take place in? I believe that a
three-class hospital in southwest China conducted this study. It is therefore necessary for you to
describe this hospital. Considering that readers must be aware of the study area's descriptions.
3.2 Research design and participants
The study design was not described.
The inclusion and exclusion criteria should be provided separately.
Ethics consent should also be provided separately.
3.4 Sample size calculation: not well written
N=Z2#PQ/d2 should be rewritten in equation form.
3.5 Study Variables
It stated that "clinical information (menopause, BMI, etc.) was ascertained by a medical record
review at the end of the study." What are the purposes of listing these variables in your study
if they were all recorded at the end?
4. Results
• The detailed process diagram (Fig. 1) should be provided in the method section.
• Provide comparisons of demographic characteristics for continuous and categorical variables
separately (Table 3 and the like).
• The majority of discussions are based on demographic characteristics. However, the discussion
doesn't produce any descriptions related to the inferential parts. As a result, provide discussions
related to results associated with inferential analysis.
Strengths and limitations
A statement said that “This study breaks the traditional steps of sexual function assessment in
breast cancer patients, based on understanding whether patients are sexually active or not, and
then conducting sexual function assessment. This study prospectively found that those aged >50
years were more sexually active than those younger, … and credibility of the findings.” Should
provide in the discussion section. In this section, you should provide only the limitations of your
study .